Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Monday 18 October, 2010

Lipoxen PLC


RNS Number : 5049U
Lipoxen PLC
18 October 2010

For Immediate Release

18 October 2010





·               Project results validate positive Efficacy findings for Proprietary Influenza Vaccine candidate
·               Company advancing plans to take product candidate into Phase 1 clinical trials within 24 months.
·               Initiation of search for commercial collaboration to accelerate product development.


Lipoxen plc (AIM: LPX), ('Lipoxen' or 'the Company') a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces positive efficacy results for its novel influenza vaccine using its liposomal co-delivery technology "ImuXen" and is advancing plans to capitalise on this pre-clinical success in order to accelerate the candidate into the clinic within 24 months.


While Lipoxen has provided interim updates to the market on this Technology Strategy Board part-funded project, the agreed project plan has now been successfully concluded with the positive outcome that the Lipoxen formulation induced protective immunity against challenge with live virulent influenza virus after a single vaccination in a mouse model.  Importantly, the formulation did not require the addition of an adjuvant and contained considerably less protein antigen than current flu vaccines.  Furthermore, a spray dried version of the vaccine was still efficacious even after storage at 37°C for 6 weeks indicating that there is the potential to create a formulation that can withstand storage outside of the cold chain.


In April 2009 the Company announced positive pre-clinical data in respect of this proprietary influenza vaccine candidate, noting that:


1.   The ImuXen technology platform, as applied to an influenza vaccine had shown an increase in the effectiveness of influenza vaccines of approximately 30-fold.

2.   The technology has the potential to radically increase output of vaccine doses from manufacturing facilities to confer an advantage of up to 10 times existing vaccine production rates -  a major benefit when addressing the challenges to human health in situation of both pandemic and seasonal outbreaks.

3.   The technology avoids the need for "cold chain" storage and distribution as in its dried form it is stable for long periods at high temperatures


Lipoxen stated at that time that it was necessary to undertake further studies to specifically validate the significant advantages that a novel influenza vaccine produced using the ImuXen platform technology could deliver. These were focused on three key areas:


(a)  Economies of production through the use of less antigen.

(b)  The ability to confer single-shot immunity

(c)  The ability to deliver a cost effective and storage and handling stable product able to be effectively dosed in tropical and sub-tropical climates.



In short, these latest project results have validated all of the major benefits announced 18 months ago and, based on them, the Company has moved directly to seek EU grant funding to assist in meeting the costs of undertaking a full GMP manufacturing and GLP toxicity, safety and efficacy programme ahead of the Company's planned route to Phase I (safety) studies in man.


Subject to the availability of capital - whether internally, from EU grant funding or through commercial partnering Lipoxen has targeted submitting its clinical trial application in Q4 2012.


Commenting on the announcement, Scott Maguire, CEO said:


"While the vaccine used in this project was designed to mimic current single-strain pandemic vaccines, the ImuXen platform allows the development of multi-valent vaccines with the potential to address the combined demands of therapeutic efficacy and cost effectiveness, the latter being in the light of the continuing demands of governments and other health care payers to reduce the cost of public healthcare.


These trial results have underpinned our belief in the long term viability of the ImuXen platform for the development and efficient production of a broad spectrum of vaccine therapies, and have wholly vindicated our early optimism for both the ImuXen technology in general and the influenza vaccine candidate in particular. We are now actively taking steps to commercialise this opportunity in parallel with seeking EU grant funding to take this important proprietary product into the clinic as soon as possible.


While a specific influenza product may yet be some years away from any market launch - and by no means taking lightly the challenges of clearing the many clinical hurdles to be overcome along the way - the Company has now put a clear line in the sand over the real commercial  potential vested in the ImuXen platform which can now look to sit alongside our PolyXen technology which has already shown such great promise in both clinical trials and with our leading commercial collaborator, Baxter Healthcare.


I believe that these results put Lipoxen firmly on the map as a leading European platform technology company with the potential to offer a full range of delivery solutions for both biologic and vaccine therapies, be this for next generation drugs and vaccines or for patent protected bio-superior products."



- Ends -


For further information, please contact:


Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer

Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång

Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Mark Court, Jessica Fontaine


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:


1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA


Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 


Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.


The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010 which was led by the Company's management team.


Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website:


About the Technology Strategy Board

The Technology Strategy Board is a business-led executive non-departmental public body, established by the government.  Its role is to promote and support research into, and development and exploitation of, technology and innovation for the benefit of UK business, in order to increase economic growth and improve the quality of life.  It is sponsored by the Department for Business, Innovation and Skills (BIS).  For further information please visit 


This information is provided by RNS
The company news service from the London Stock Exchange